Graves Disease, Hyperthyroidism
Conditions
Keywords
Heart rate; Pulse rate
Brief summary
The investigators want to investigate if a continuous heart rate monitoring with a wrist worn fitnesstracker can be useful in the treatment and surveillance of patients suffering from Graves' disease.The aim of our research project is two-fold: First, to evaluate the use of continuous heart rate monitoring as a potential substitute for hormone measurements during treatment of hyperthyroidism. Second, to use continuous heart rate monitoring as a tool for early detection of relapse after discontinuation of antithyroid drugs.
Interventions
DIAGNOSTIC_TESTContinuous heart rate monitoring
Continuous heart rate monitoring with a wrist worn fitnesstracker
Sponsors
University Hospital, Basel, Switzerland
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
All participants: * BMI 17 to 35 kg/m2 * Diagnosis of Graves' disease (matching one of the following criteria: elevated TRAb and/or ultrasonography and functional imaging consistent with Graves' disease) * In possession of a smart phone * Able to use a wearable device and willing to regularly upload their biometric data * Informed consent as documented by signature (Appendix Informed Consent Form) Group treatment: * TSH \< 0.2 mIU/l and * fT4 \> 25 pM or fT3 \> 8 pM * ATD planned, additional treatment with propranolol allowed Group surveillance: * TSH within the reference range between 0.3 and 4.5 mlU/l * Cessation of ATD is planned within the next 2-4 weeks
Exclusion criteria
* Chronic treatment with beta blocker or verapamil-type calcium antagonist for other reason than symptomatic treatment of hyperthyroidism (propranolol) * Treatment with amiodarone * Pacemaker with continuous stimulation. * Severe concomitant diseases: chronic heart failure, liver cirrhosis, kidney failure, active cancer * Abuse of alcohol or illicit drugs * Allergic to nickel or silicone * Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| resting heart rate | four months | continuous resting heart rate measurement with fitnesstracker in relation to the thyroid hormone levels in patients during and after treatment with anti-thyroid drugs. |
Countries
Switzerland
Outcome results
None listed